Expertise in
35
conditions

Dr. James Radford

Oncology
Hendersonville Hematology And Oncology@Pardee
1824 Pisgah Dr, 
Hendersonville, NC 
Clinical Trials:Currently Recruiting for 2 Trials
Offers Telehealth
Expertise in
35
conditions
Hendersonville Hematology And Oncology@Pardee
1824 Pisgah Dr, 
Hendersonville, NC 

Overview

James Radford is an Oncologist practicing medicine in Hendersonville, North Carolina.

Dr. Radford is highly rated in 35 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Neuroendocrine Tumor, Colorectal Cancer, Urothelial Cancer, and Endoscopy.

He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 95 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in NC

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Hendersonville Hematology and Oncology@Pardee
1824 Pisgah Dr, Hendersonville, NC 28791
Other Locations
Office
800 N Justice St, Hendersonville, NC 28791

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

94 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: June 18, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Enrollment Status: Recruiting
Publish Date: June 18, 2026
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 2
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Bendamustine Hydrochloride, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Obinutuzumab, Prednisone, Umbralisib, Vincristine Sulfate
Study Phase: Phase 2
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
View 8 Less Clinical Trials

1 Total Publications

Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer.
Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 02, 2013
Similar Doctors
Expertise in
39
conditions
Expertise in
39
conditions
Referral may be required

Gibbs Cancer Center And Research Institute

2759 South Highway 14, 
Greer, SC 
 (21.9 miles away)
864-849-9700
Experience:
24+ years
Languages Spoken:
English
See accepted insurances

Carlton Schwab is an Oncologist practicing medicine in Greer, South Carolina. He has been practicing medicine for over 24 years. Dr. Schwab is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Ovarian Carcinosarcoma, Endometrial Cancer, Ovarian Cancer, Bladder Reconstruction, and Hernia Surgery. Dr. Schwab is board certified in American Board Of Obstetrics & Gynecology, (Obstetrics & Gynecology, Gynecologic Oncology), and (Obstetrics & Gynecology).

Expertise in
27
conditions
Expertise in
27
conditions
Referral may be required

Hope Women's Cancer Center

100 Ridgefield Ct, 
Asheville, NC 
 (18.8 miles away)
828-670-8403
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Timothy Vanderkwaak is an Oncologist practicing medicine in Asheville, North Carolina. Dr. Vanderkwaak is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Malignant Mixed Mullerian Tumor, Ovarian Cancer, Virilizing Ovarian Tumor, Oophorectomy, and Hernia Surgery.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

Hope Women's Cancer Center

100 Ridgefield Ct, 
Asheville, NC 
 (18.8 miles away)
828-670-8403
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ashley Case is an Oncologist practicing medicine in Asheville, North Carolina. Dr. Case is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Vulvar Cancer, Lump in the Abdomen, Malignant Mixed Mullerian Tumor, Hysterectomy, and Oophorectomy.

Frequently Asked Questions about Dr. James Radford

How do I make an appointment with Dr. James Radford?

You can book an appointment with Dr. James Radford by calling their office at 828-692-8045. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. James Radford a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. James Radford is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. James Radford specialize in?

While Dr. James Radford is a Oncology, they have specific expertise in Lung Cancer, Neuroendocrine Tumor, and Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. James Radford participate in research or clinical trials?

Yes. Dr. James Radford has published 1 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. James Radford's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. James Radford accept my insurance?

Dr. James Radford accepts most major insurance plans, including Anthem BCBS and Change Healthcare. We recommend calling the office directly at 828-692-8045 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Radford's expertise for a condition
ConditionClose
    View All 30 Advanced Conditions
    View All 105 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile